ABSTRACT
BACKGROUND: Guidelines recommend extended venous thromboembolism (VTE) prophylaxis for high-risk populations undergoing major abdominal cancer operations. Few studies have evaluated extended VTE prophylaxis in the Medicare population who are at higher risk due to age.
METHODS: We performed a retrospective study using a 20% random sample of Medicare claims, 2012-2017. Patients ≥65 years with an abdominal cancer undergoing resection were included. Primary outcome was the proportion of patients receiving new extended VTE prophylaxis prescriptions at discharge. Secondary outcomes included postdischarge VTE and hemorrhagic events.
RESULTS: The study included 72 983 patients with a mean age of 75. Overall, 8.9% of patients received extended VTE prophylaxis. This proportion increased (7.2% in 2012, 10.6% in 2017; p < 0.001). Incidence of postdischarge hemorrhagic events was 1.0% in patients receiving extended VTE prophylaxis and 0.8% in those who did not. The incidence of postdischarge VTE events was 5.2% in patients receiving extended VTE prophylaxis and 2.4% in those who did not.
CONCLUSION: Adherence to guideline-recommended extended VTE prophylaxis in high-risk patients undergoing major abdominal cancer operations is low. The higher rate of VTE in the prophylaxis group may suggest we captured some therapeutic anticoagulation, which would mean the actual rate of thromboprophylaxis is lower than reported herein.
PMID:37800390 | DOI:10.1002/jso.27473
03:11
PubMed articles on: Cancer & VTE/PE
Risk and timing of venous thromboembolism after surgery for lung cancer: a nationwide cohort study
03:11
PubMed articles on: Cardio-Oncology
03:11
PubMed articles on: Cardio-Oncology
03:11
PubMed articles on: Cancer & VTE/PE
Pulmonary Embolism Unplugged: Catheter-Directed Therapies for Intermediate-Risk Pulmonary Embolism
03:11
PubMed articles on: Cancer & VTE/PE
Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients
03:11
PubMed articles on: Cancer & VTE/PE
Unveiling Lung Adenocarcinoma: Non-bacterial Thrombotic Endocarditis as the Debut Sign
03:11
PubMed articles on: Cancer & VTE/PE
A Novel Model to Prevent Venous Thromboembolism in Patients with Lung Cancer
03:11
PubMed articles on: Cancer & VTE/PE
Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis
03:11
PubMed articles on: Cardio-Oncology
07:08
Cardiotoxicity News
PubMed articles on: Cardio-Oncology
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction
JACC Heart Fail. 2023 Oct 12:S2213-1779(23)00596-6. doi: 10.1016/j.jchf.2023.08.026. Online ahead of print.
No comments:
Post a Comment
اكتب تعليق حول الموضوع